Glaukos Corp Reports 10-K Results, Shares Rise 5.03%

By Chris Stiles • Monday, February 23 10:39 • Permanent Link

Glaukos Corp recently released its 10-K report, detailing its operations as an ophthalmic pharmaceutical and medical technology company. The company focuses on developing therapies for glaucoma, corneal disorders, and retinal diseases. Its flagship products include the iStent and iStent inject W micro-bypass stents, iDose TR, iLink, ILution, and retinal XR platform. Glaukos Corp sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors.

In the financial overview, Glaukos Corp reported net sales of $507,442 for the year ended December 31, 2025, compared to $383,481 for the same period in 2024. The gross margin decreased to 56% in 2025 from 75% in 2024, while operating expenses amounted to $482,361 in 2025, up from $411,820 in 2024. The company's cash, cash equivalents, short-term investments, and restricted cash totaled $282,594 as of December 31, 2025, down from $323,648 in 2024. Glaukos Corp incurred net losses of $187.7 million, $146.4 million, and $134.7 million for the years ended December 31, 2025, 2024, and 2023, respectively, with an accumulated deficit of $933.1 million as of December 31, 2025.

In recent developments, Glaukos Corp received U.S. FDA approval for Epioxa, an advancement in keratoconus care, and obtained EU Medical Device Regulation certification for its iStent family of products. The company also acquired Mobius Therapeutics, LLC and purchased real property adjacent to its corporate headquarters. The report also discussed the impact of the global economic environment, foreign currency fluctuations, and developments affecting reimbursement rates and coverage in the U.S. healthcare system.

As for the business outlook, Glaukos Corp anticipates increased utilization of iDose TR as reimbursement becomes more timely and consistent across all Medicare Administrative Contractors. The company also expects potential disruption within its U.S. Corneal Health franchise as the market transitions from Photrexa to Epioxa following its approval.

These specific figures and developments outlined in the 10-K report provide a comprehensive view of Glaukos Corp's financial performance, strategic initiatives, and market outlook. Today the company's shares have moved 5.03% to a price of $120.24. For the full picture, make sure to review GLAUKOS Corp's 10-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.